

August 12, 2025

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Noritaka Narimiya
Executive Corporate Officer and Chief Financial Officer
TEL: +81-3-5472-1125

Notice Regarding Adjustment of Exercise Price

SymBio Pharmaceuticals Limited (the “Company”) hereby announces that, in conjunction with the issuance of the 65th to 67th Stock Acquisition Rights through a third-party allotment to EVO FUND, as resolved at the Board of Directors meeting held on Tuesday, July 22, 2025, the exercise price of the stock acquisition rights will be revised as follows.

1. Adjustment of Exercise Price

Name of stock acquisition rights	Exercise price after adjustment	Exercise price before adjustment
SymBio Pharmaceuticals Limited's 58th Stock Acquisition Rights	¥155.0	¥157.5

2. Applicable Date

From Tuesday, August 12, 2025

3. Reason for Adjustment

The exercise price will be adjusted because the revised conversion price of the 7th Unsecured Convertible Bonds with Stock Acquisition Rights issued to Cantor Fitzgerald Europe, as a result of the issuance of the 65th to 67th Stock Acquisition Rights through a third-party allotment to EVO FUND, as resolved at the Board of Directors meeting held on Tuesday, July 22, 2025, is lower than the effective exercise price on the applicable start date stipulated in Item 10, Clause (2)-3) of the Terms and Conditions of the 58th Stock Acquisition Rights.